StockData
Bristol Myers Squibb Co logo

Bristol Myers Squibb Co (BMY) revenue by segment

BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 15/3032% below fair value
$58.34−1.22 (-2.05%)

Close on Nov 19, 2026Market cap $119.25BP/E 12.9Yield 4.27%

Doanh thu theo bộ phận của Bristol Myers Squibb Co

Theo bộ phận kinh doanh

Theo sản phẩm hoặc dịch vụ

Doanh thuFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016% doanh thuYoY
Gross product sales$88.09B$83.67B$73.68B$69.63B$67.90B$60.02B––––182.8%+5.3%
Net product sales$46.76B$46.78B$43.78B$44.67B$45.06B$41.32B––––97.0%-0.0%
Growth Portfolio$26.41B$22.56B$19.37B$16.76B––––––54.8%+17.0%
Legacy Portfolio$21.79B$25.74B$25.64B$29.40B––––––45.2%-15.4%
Eliquis$14.44B$13.33B$12.21B$11.79B$10.76B$9.17B$7.93B$6.44B$4.87B$3.34B30.0%+8.3%
Opdivo$10.05B$9.30B$9.01B$8.25B$7.52B$6.99B$7.20B$6.74B$4.95B$3.77B20.9%+8.0%
Orencia$3.71B$3.68B$3.60B$3.46B$3.31B$3.16B$2.98B$2.71B$2.48B$2.27B7.7%+0.6%
Revlimid$2.95B$5.77B$6.10B$9.98B$12.82B$12.11B$1.30B$0$0–6.1%-48.9%
Yervoy$2.90B$2.53B$2.24B$2.13B$2.03B$1.68B$1.49B$1.33B$1.24B$1.05B6.0%+14.6%
Pomalyst/Imnovid$2.73B$3.55B$3.44B$3.50B$3.33B$3.07B$322.00M$0$0–5.7%-22.9%
Reblozyl$2.33B$1.77B$1.01B$717.00M$551.00M$274.00M$0$0––4.8%+31.2%
Other Growth products$1.92B$1.64B$1.21B$1.09B––––––4.0%+17.1%
Alliance and other revenues$1.44B$1.52B$1.23B$1.49B$1.33B$1.20B––––3.0%-5.5%
Breyanzi$1.36B$747.00M$364.00M$182.00M$87.00M$0$0–––2.8%+81.8%
Opdualag$1.19B$928.00M$627.00M$252.00M$0$0––––2.5%+27.7%
Camzyos$1.07B$602.00M$231.00M$24.00M$0$0––––2.2%+77.4%
Other revenues$992.00M$1.04B$620.00M$746.00M$614.00M$582.00M––––2.1%-4.9%
Other Legacy products$798.00M$925.00M$962.00M$1.16B––––––1.7%-13.7%
Zeposia$577.00M$566.00M$434.00M$250.00M$134.00M$12.00M$0$0––1.2%+1.9%
Sprycel$493.00M$1.29B$1.93B$2.17B$2.12B$2.14B$2.11B$2.00B$2.01B$1.82B1.0%-61.7%
Alliance revenues$447.00M$479.00M$608.00M$742.00M$716.00M$615.00M––––0.9%-6.7%
Abecma$427.00M$406.00M$472.00M$388.00M$164.00M$0$0–––0.9%+5.2%
Abraxane$368.00M$875.00M$1.00B$811.00M$1.18B$1.25B$166.00M$0$0–0.8%-57.9%
Sotyktu$291.00M$246.00M$170.00M$8.00M$0$0––––0.6%+18.3%
Opdivo Qvantig$238.00M$0$0–––––––0.5%–
Krazati$205.00M$126.00M$0$0––––––0.4%+62.7%
Cobenfy$155.00M$10.00M$0$0––––––0.3%+1450.0%
Augtyro–$38.00M$1.00M$0$0–––––––
Mature and other brands––$1.90B$2.05B$2.23B$2.22B$2.29B$2.36B$3.95B$2.27B––
Inrebic––$110.00M$85.00M$74.00M$55.00M$5.00M$0$0–––
Onureg––$168.00M$124.00M$73.00M$17.00M$0$0––––
Total Recent LOE Products––$7.10B$10.79B$14.00B–––––––
In-line products and new product portfolio––$37.91B$35.37B$32.38B–––––––
In-line products––$34.32B$33.34B$31.30B–––––––
New product portfolio––$3.59B$2.03B$1.08B–––––––
Empliciti–––$296.00M$334.00M$381.00M$357.00M$247.00M$231.00M$150.00M––
Baraclude–––––$447.00M$555.00M$744.00M$1.05B$1.19B––
Vidaza–––––$455.00M$58.00M$0$0–––
Sustiva Franchise–––––––$283.00M$729.00M$1.07B––
Reyataz–––––––$427.00M$698.00M$912.00M––
Hepatitis C Portfolio–––––––$17.00M$406.00M$1.58B––
Abilify–––––––––$128.00M––

Theo khu vực

Doanh thuFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016% doanh thuYoY
U S$33.28B$34.11B$31.21B$31.50B$29.21B$26.58B$15.34B$12.59B$11.36B$10.72B69.1%-2.4%
International$13.83B$13.20B$13.10B$13.83B$16.32B$15.31B$6.27B$5.66B$4.99B$4.22B28.7%+4.8%
Other$1.09B$996.00M$699.00M$834.00M$852.00M$631.00M$524.00M$584.00M$553.00M$528.00M2.3%+9.1%
Europe––––––––$4.99B$4.22B––
Rest of the World––––$5.63B$5.46B$4.01B$3.73B$3.88B$3.96B––

Lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K, 10-Q của Bristol Myers Squibb (XBRL). Số quý 4 bằng cả năm tài chính trừ chín tháng đầu. Tên bộ phận giữ theo cách công ty tự đặt và có thể đổi khi công ty tái cấu trúc. Tab KPI hiện các bộ phận này cạnh chỉ số vận hành của Bristol Myers Squibb, kèm đầy đủ lịch sử, biểu đồ và liên kết tới từng hồ sơ.

See a number that looks wrong?